Literature DB >> 17038469

The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.

M P Cancro1.   

Abstract

The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038469      PMCID: PMC1798379          DOI: 10.1136/ard.2006.058412

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  37 in total

1.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

2.  Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire.

Authors:  J G Cyster; S B Hartley; C C Goodnow
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

3.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.

Authors:  P A Moore; O Belvedere; A Orr; K Pieri; D W LaFleur; P Feng; D Soppet; M Charters; R Gentz; D Parmelee; Y Li; O Galperina; J Giri; V Roschke; B Nardelli; J Carrell; S Sosnovtseva; W Greenfield; S M Ruben; H S Olsen; J Fikes; D M Hilbert
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

Review 4.  The BAFF/APRIL system: an important player in systemic rheumatic diseases.

Authors:  Fabienne Mackay; Frederic Sierro; Shane T Grey; Tom P Gordon
Journal:  Curr Dir Autoimmun       Date:  2005

Review 5.  Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.

Authors:  Diane F Jelinek; Jaime R Darce
Journal:  Curr Dir Autoimmun       Date:  2005

6.  Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity.

Authors:  A G Rolink; J Andersson; F Melchers
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

7.  Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.

Authors:  Sarah G Hymowitz; Darshana R Patel; Heidi J A Wallweber; Steven Runyon; Minhong Yan; Jianping Yin; Stephanie K Shriver; Nathaniel C Gordon; Borlan Pan; Nicholas J Skelton; Robert F Kelley; Melissa A Starovasnik
Journal:  J Biol Chem       Date:  2004-11-12       Impact factor: 5.157

Review 8.  The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.

Authors:  Michael P Cancro
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

9.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help.

Authors:  D A Fulcher; A B Lyons; S L Korn; M C Cook; C Koleda; C Parish; B Fazekas de St Groth; A Basten
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 2.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

3.  B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.

Authors:  E Becerra; I De La Torre; M J Leandro; G Cambridge
Journal:  Clin Exp Immunol       Date:  2017-09-25       Impact factor: 4.330

Review 4.  Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?

Authors:  Ismael Calero; Iñaki Sanz
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

5.  Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice.

Authors:  Meera Ramanujam; Ramalingam Bethunaickan; Weiqing Huang; Haiou Tao; Michael P Madaio; Anne Davidson
Journal:  Arthritis Rheum       Date:  2010-05

Review 6.  BAFF: a local and systemic target in autoimmune diseases.

Authors:  I Moisini; A Davidson
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

Review 7.  Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination.

Authors:  Zhenming Xu; Egest J Pone; Ahmed Al-Qahtani; Seok-Rae Park; Hong Zan; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2007       Impact factor: 2.214

8.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.

Authors:  Troy D Querec; Rama S Akondy; Eva K Lee; Weiping Cao; Helder I Nakaya; Dirk Teuwen; Ali Pirani; Kim Gernert; Jiusheng Deng; Bruz Marzolf; Kathleen Kennedy; Haiyan Wu; Soumaya Bennouna; Herold Oluoch; Joseph Miller; Ricardo Z Vencio; Mark Mulligan; Alan Aderem; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-11-23       Impact factor: 25.606

9.  Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

Authors:  Annett M Jacobi; Weiqing Huang; Tao Wang; William Freimuth; Inaki Sanz; Richard Furie; Meggan Mackay; Cynthia Aranow; Betty Diamond; Anne Davidson
Journal:  Arthritis Rheum       Date:  2010-01

10.  Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.

Authors:  E Becerra; M A Scully; M J Leandro; E O Heelas; J-P Westwood; I De La Torre; G Cambridge
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.